Researchers have created a new vitamin B12 delivery system using tiny fat-based capsules that release B12 slowly over 5 days instead of just 1.5 hours, potentially reducing injections for children with methylmalonic acidemia. According to Gram Research analysis, the new formulation extended how long B12 remains active in the body from 1.5 hours to 121.42 hours and delivered 191.89% more usable B12 to the body compared to regular B12. While animal testing shows promise with no serious safety concerns, human clinical trials are still needed before this treatment can be used in patients.
Researchers have developed a new way to deliver vitamin B12 that stays in the body much longer than current treatments. The innovation uses tiny fat-based capsules called multivesicular liposomes to hold B12 and release it slowly over a week. This breakthrough could help children with a rare genetic disorder called methylmalonic acidemia, who currently need frequent painful injections. According to Gram Research analysis, the new formulation extended how long B12 stays active in the body from 1.5 hours to over 5 days, potentially reducing treatment burden and improving quality of life for young patients.
Key Statistics
A 2026 laboratory study found that vitamin B12-loaded multivesicular liposomes extended the time B12 remains active in the body from 1.5 hours to 121.42 hours, a roughly 81-fold increase in duration.
Research published in the International Journal of Pharmaceutics: X showed that the new B12 capsule formulation achieved 92.43% encapsulation efficiency and delivered 191.89% relative bioavailability compared to standard vitamin B12.
The new B12 delivery system maintained the lipid phase at the injection site for more than 4 days while sustaining B12 release for up to 7 days, compared to standard B12 which is metabolized within hours.
The Quick Take
- What they studied: A new way to deliver vitamin B12 that releases slowly in the body instead of all at once, designed to reduce how often children need injections for a rare metabolic disorder.
- Who participated: This was laboratory and animal research testing a new B12 delivery system. Human clinical trials have not yet been conducted.
- Key finding: The new B12 capsules kept the vitamin active in the body for over 5 days compared to just 1.5 hours with regular B12, and delivered nearly twice as much usable B12 to the body.
- What it means for you: If approved for human use, children with methylmalonic acidemia could potentially receive B12 treatment once a week instead of multiple times per week, reducing painful injections and improving daily life. However, human testing is still needed to confirm safety and effectiveness.
The Research Details
Scientists created tiny capsules made of fat-like material called liposomes that can hold and slowly release vitamin B12. They used a special technique called microfluidic double-emulsification, which is like creating multiple layers of tiny bubbles within bubbles. To solve the problem that B12 doesn’t mix well with fat, they added a helper molecule called dimethyl-beta-cyclodextrin that acts like a bridge, allowing more B12 to fit inside the capsules.
The researchers tested these capsules in laboratory settings and in animal models to see how long the B12 stayed in the body and how much actually reached the bloodstream. They measured how long the capsules remained at the injection site and tracked how the B12 was released over time. They also performed safety tests to make sure the capsules didn’t damage cells or cause harmful reactions.
This type of research is important because it bridges the gap between laboratory discovery and potential human treatments. By testing in animals first, scientists can understand how the system works in a living body before attempting human trials.
Current B12 treatments for methylmalonic acidemia have major problems: injections hurt and patients don’t like getting them frequently, while oral pills don’t work well because B12 isn’t absorbed reliably from the stomach. A long-acting delivery system could transform treatment by reducing injection frequency, improving patient compliance, and potentially preventing serious complications from inconsistent B12 levels.
This research was published in a peer-reviewed pharmaceutical journal, indicating it met scientific standards for evaluation. The study used multiple testing methods including laboratory analysis, animal models, and safety evaluations. However, this is early-stage research that has not yet been tested in humans. The sample size for animal studies was not specified in the abstract. Before this treatment could be used in children, it would need to pass human clinical trials to confirm safety and effectiveness.
What the Results Show
The new B12 capsules had a distinctive honeycomb-like structure with uniform size and could hold a high amount of B12 (92.43% encapsulation efficiency). When the helper molecule was added, the amount of B12 that could fit inside increased by 60%, from 10.96 to 17.60 milligrams per milliliter.
Most importantly, the capsules dramatically extended how long B12 stayed active in the body. Regular B12 had a mean residence time of only 1.5 hours, meaning most of it was gone within hours. The new capsules extended this to 80.69 hours (about 3.4 days), and with the helper molecule added, it reached 121.42 hours (about 5 days). This means patients could potentially go much longer between treatments.
The relative bioavailability was 191.89%, meaning the body absorbed nearly twice as much usable B12 from the new capsules compared to regular B12. The capsules released B12 gradually: the fatty part of the capsule stayed at the injection site for more than 4 days, while the water-based part continued releasing B12 for up to 7 days.
Safety testing showed no damage to red blood cells, minimal irritation to tissues at the injection site, and no concerning changes in blood tests or blood chemistry. These preliminary results suggest the capsules are well-tolerated, though more extensive safety testing in humans would be needed before clinical use.
This research represents a significant advancement over existing B12 delivery methods. Current intramuscular injections require frequent administration (often weekly or monthly) and cause discomfort. Oral B12 supplements have unpredictable absorption and don’t work reliably for patients with methylmalonic acidemia. The new sustained-release system combines the reliability of injections with the convenience of less frequent dosing, potentially offering the best of both approaches.
This research was conducted in laboratory and animal models only, not in humans. The exact sample size for animal studies was not reported. Long-term safety data in living subjects is limited. The formulation has not been tested for stability over extended storage periods. Before this treatment could be used in children, it would require human clinical trials to confirm that the benefits seen in animals translate to real patients and that no unexpected side effects occur.
The Bottom Line
This research shows strong promise for a new B12 delivery method that could reduce treatment burden for children with methylmalonic acidemia. However, these findings are preliminary and based on laboratory and animal studies. Patients and families should not expect this treatment to be available immediately. The next steps involve human clinical trials to confirm safety and effectiveness. Discuss any interest in participating in future trials with your healthcare provider.
This research is most relevant to families of children with methylmalonic acidemia, a rare genetic disorder affecting B12 metabolism. It may also interest healthcare providers treating this condition and researchers developing improved drug delivery systems. People taking B12 supplements for other reasons should not assume this technology will be available for their use in the near future.
If human trials begin soon, it typically takes 5 to 10 years for a new pharmaceutical formulation to move from animal testing through clinical trials and regulatory approval. Realistic expectations would place potential availability at least 5 to 7 years in the future, assuming successful human trials and regulatory approval.
Frequently Asked Questions
How does the new B12 delivery system work differently from regular B12 injections?
The new system uses tiny fat-based capsules that release B12 slowly over 5 to 7 days instead of all at once. This means B12 stays active in the body much longer (121 hours versus 1.5 hours), potentially allowing patients to receive injections less frequently while maintaining consistent B12 levels.
When will this new B12 treatment be available for patients?
This research is still in early stages with animal testing completed. Human clinical trials have not yet begun. Typically, new pharmaceutical treatments require 5 to 10 years of testing and regulatory approval after animal studies. Realistic availability would be at least 5 to 7 years away, assuming successful human trials.
Is this new B12 formulation safe based on the research?
Preliminary safety testing in animals showed no damage to red blood cells, minimal tissue irritation, and no concerning changes in blood chemistry. However, extensive human safety testing is still needed before this treatment can be used in patients. Animal safety data does not guarantee human safety.
Who would benefit most from this new B12 delivery system?
Children with methylmalonic acidemia, a rare genetic disorder affecting B12 metabolism, would benefit most. This group currently requires frequent painful injections. The new system could reduce injection frequency and improve quality of life while maintaining therapeutic effectiveness.
How much more B12 does the new capsule system deliver compared to regular B12?
The new formulation delivers 191.89% relative bioavailability, meaning the body absorbs nearly twice as much usable B12 compared to standard vitamin B12. Additionally, adding a helper molecule increased the B12 concentration inside the capsules by 60%, from 10.96 to 17.60 milligrams per milliliter.
Want to Apply This Research?
- Track injection frequency and dates, noting any changes in energy levels, cognitive function, or symptoms of B12 deficiency. Record any side effects or injection site reactions. Once this treatment becomes available, users could track time between doses and compare symptom patterns.
- For current B12 patients, use the app to set reminders for scheduled injections and document how you feel before and after treatment. This data could be valuable to share with your doctor and would help establish a baseline for comparison if you transition to a new long-acting formulation.
- Establish a baseline of current symptoms, energy levels, and injection schedule. If new treatments become available, continue tracking the same metrics to objectively measure whether the new formulation improves quality of life and reduces treatment burden compared to current therapy.
This research describes early-stage laboratory and animal testing of a new vitamin B12 delivery system. It has not been tested in humans and is not yet available for clinical use. This article is for informational purposes only and should not be considered medical advice. Patients with methylmalonic acidemia should continue their current prescribed B12 treatment and consult with their healthcare provider about any questions regarding new treatments. Do not attempt to modify or discontinue B12 therapy without medical supervision. Always discuss new treatment options with your doctor before making any changes to your medical care.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.